Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease

Kurata, Seiji; Ishibashi, Masatoshi; Azuma, Koichi; Kaida, Hayato; Takamori, Shinzo; Fujimoto, Kiminori; Kobayashi, Maiko; Hirose, Yasumitsu; Aizawa, Hisamichi; Hayabuchi, Naofumi

doi:10.1007/s11604-010-0449-6

Cited by 12 publications

(7 citation statements)

References 21 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PET is based on the differential metabolism of normal and abnormal tissues, and the uptake of 18 F-FDG is usually accelerated in tumor cells. Because some pleural inflammatory and infectious lesions can also induce increased 18 F-FDG uptake, the underlying diseases may display false-positive findings, leading to a low diagnostic accuracy for PET-CT. To improve diagnostic ability, various methods of interpreting PET-CT, including the use of SUV threshold, ratio of SUV of pleural lesions to that of mediastinum, and dual-time-point PET have been proposed [ 9 , 10 , 17 , 18 ]. However, the concern about false-negative results still remains.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of the PET-CT score for diagnosis of malignant pleural effusion

Yang

Tong

Wang

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Although some parameters of positron emission tomography with 18 F-fluorodeoxyglucose ( 18 F-FDG) and computed tomography (PET-CT) are somehow helpful in differentiating malignant pleural effusion (MPE) from benign effusions, no individual parameter offers sufficient evidence for its implementation in the clinical practice. The aim of this study was to establish the diagnostic accuracy of a scoring system based on PET-CT (the PET-CT score) in diagnosing MPE. Methods One prospective derivation cohort of patients with pleural effusions (84 malignant and 115 benign) was used to develop the PET-CT score for the differential diagnosis of malignant pleural effusion. The PET-CT score was then validated in another independent prospective cohort ( n = 74). Results The PET-CT parameters developed for discriminating MPE included unilateral lung nodules and/or masses with increased 18 F-FDG uptake (3 points); extrapulmonary malignancies (3 points); pleural thickening with increased 18 F-FDG uptake (2 points); multiple nodules or masses (uni- or bilateral lungs) with increased 18 F-FDG uptake (1 point); and increased pleural effusion 18 F-FDG uptake (1 point). With a cut-off value of 4 points in the derivation cohort, the area under the curve, sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio of the PET-CT score to diagnose MPE were 0.949 (95% CI: 0.908–0.975), 83.3% (73.6%–90.6%), 92.2% (85.7%–96.4%), 10.7 (5.6–20.1), and 0.2 (0.1–0.3), respectively. Conclusions A simple-to-use PET-CT score that uses PET-CT parameters was developed and validated. The PET-CT score can help physicians to differentiate MPE from benign pleural effusions. Electronic supplementary material The online version of this article (10.1007/s00259-019-04287-7) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and validation of the PET-CT score for diagnosis of malignant pleural effusion

Yang

Tong

Wang

et al. 2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Kurata et al have investigated the role of PET and osteopontin levels in asbestos related pleural disease and concluded that malignant mesothelioma has significantly higher uptake than benign asbestos related pleural disease (1). There is limited number of studies in the literature about asbestos related pleural disease in the literature (3).…”

Section: Discussionmentioning

confidence: 99%

“…There is limited number of studies in the literature about asbestos related pleural disease in the literature (3). Kurata et al accepted a SUV max level of 4.1 and orki et al as 3.0 for determination of malignancy (1,3). However the authors stressed about the epitheloid subtype of malignant mesothelioma which is a slow growing variant of the group that has SUV max levels around 2.0 (1).…”

Section: Discussionmentioning

confidence: 99%

“…The first line imaging modality is computed tomography (CT) which can determine the extent of disease (invasion to adjacent structures; mediastinal or dyafragmatic) and accompanying parenchyma or nodal involvement. However CT or magnetic resonance (MR) imaging cannot differentiate malignant and benign pleural plaques sufficiently (1). F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) is a discriminative imaging modality in various types of malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The F-18 FDG PET/CT and CT evaluation of pleural plaques

et al. 2019

View full text Add to dashboard Cite

The F-18 Fdg PeT/cT and cT evaluation of pleural plaques Introduction: Pleural plaques have the possibility of bearing malignancy thus investigation of this entity is important and the most important indicator of malignancy in general is fluorodeoxyglucose (FDG) accumulation in radiological appearance. However there is discrepancy between results of previous studies in the literature about this subject. The aim of this study is to analyze the standardized uptake value of pleural plaques and the cut off levels for malignancy in comparison with computed tomography (CT). Materials and Methods: Seventy one patients were included in the study (27F, 44M; mean: 59.9 ± 13.1 years). Oncologic F-18 FDG positron emission tomography/computed tomography (PET/CT) was performed to all the subjects for a different primary tumor. Pleural plaques were identified in all patients in CT component of PET/CT examination. Contrast enhanced and nonenhanced CT images were evaluated by a Radiology Physician independently according to the gold standard pathology. results: The diagnostic sensitivity, specificity of CT was; 39%, 79% respectively and if the cutoff SUV max level was accepted "4.8" the diagnostic sensitivity and specificity of PET was 71%, and 63% respectively.

show abstract

“…The role of positron emission tomography (PET) and integrated PETcomputer tomography (PET-CT) with [18] F-Fluorodeoxyglucose (FDG) in predicting malignancy in patients with pleural effusion or pleural thickening is still debated. The existing three earlier systematic reviews and meta-analyses were published in 2014 and 2015, included also noneffusion pleural pathology [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22], handled bias differently, and reached different and contradictory conclusions [23][24][25]. Five studies have been published since then [26][27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease

Abstract: PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.

Cited by 12 publications

References 21 publications

Development and validation of the PET-CT score for diagnosis of malignant pleural effusion

Development and validation of the PET-CT score for diagnosis of malignant pleural effusion

The F-18 FDG PET/CT and CT evaluation of pleural plaques

Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis

Contact Info

Product

Resources

About